Skip to main content
Erschienen in: Annals of Surgical Oncology 3/2020

11.10.2019 | Thoracic Oncology

Impact of Lymphadenectomy on Survival After Unimodality Transthoracic Esophagectomy for Adenocarcinoma of Esophagus

verfasst von: A. W. Phillips, MD, MA, FRCSEd (Gen.Surg), K. Hardy, BSc, M. Navidi, MB, ChB, FRCSEd (Gen.Surg), S. K. Kamarajah, BMedSci, MBChB, A. Madhavan, MB, ChB, MRCS, A. Immanuel, MD, FRCSEd, S. M. Griffin, OBE, MD, PRCSEd

Erschienen in: Annals of Surgical Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Debate remains regarding the extent of lymphadenectomy required with esophagectomy. In patients who receive neoadjuvant treatment, this may address lymph node metastases. However, patients with early disease and those with comorbidities may not receive neoadjuvant treatment. The aim of this study is to determine the impact of lymph node yield and location on prognosis in patients undergoing esophagectomy without neoadjuvant treatment.

Patients and Methods

Data from consecutive patients with potentially curable adenocarcinoma of the esophagus or gastroesophageal junction were reviewed. Patients were treated with transthoracic esophagectomy and two-field lymphadenectomy. Outcomes according to lymph node yield were determined. The prognosis of carrying out less radical lymphadenectomy was calculated according to three groups: exclusion of proximal thoracic nodes (group 1), minimal abdominal lymphadenectomy (group 2), and minimal abdominal and thoracic lymphadenectomy (group 3).

Results

357 patients were included. Median survival was 78 months [confidence interval (CI) 53–103 months]. Absolute lymph node retrieval was not related to survival (p = 0.920). An estimated additional 4 (2–6) cancer-related deaths was projected if group 1 nodes were omitted, 15 (11–19) additional deaths if group 2 nodes were omitted, and 4 (2–6) deaths if group 3 nodes were omitted. Minimal lymphadenectomy (groups 1, 2, and 3) was projected to lead to 19 (15–23) additional cancer-related deaths.

Conclusions

Extensive lymphadenectomy allows accurate staging. In patients who do not receive neoadjuvant treatment, it may confer a survival benefit. The number of lymph nodes retrieved may not be a good surrogate for extent of lymphadenectomy, and correlation with location is required.
Literatur
2.
Zurück zum Zitat Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062–7.PubMedCrossRef Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062–7.PubMedCrossRef
3.
Zurück zum Zitat Rizk NP, Ishwaran H, Rice TW, Chen L-Q, Schipper PH, Kesler KA, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010;251(1):46–50.PubMedCrossRef Rizk NP, Ishwaran H, Rice TW, Chen L-Q, Schipper PH, Kesler KA, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010;251(1):46–50.PubMedCrossRef
4.
Zurück zum Zitat Visser E, Markar SR, Ruurda JP, Hanna GB, van Hillegersberg R. Prognostic value of lymph node yield on overall survival in esophageal cancer patients. Ann Surg. 2018;1. Visser E, Markar SR, Ruurda JP, Hanna GB, van Hillegersberg R. Prognostic value of lymph node yield on overall survival in esophageal cancer patients. Ann Surg. 2018;1.
5.
Zurück zum Zitat Boshier PR, Anderson O, Hanna GB. Transthoracic versus transhiatal esophagectomy for the treatment of esophagogastric cancer: a meta-analysis. Ann Surg. 2011;254(6):894–906.CrossRefPubMed Boshier PR, Anderson O, Hanna GB. Transthoracic versus transhiatal esophagectomy for the treatment of esophagogastric cancer: a meta-analysis. Ann Surg. 2011;254(6):894–906.CrossRefPubMed
6.
Zurück zum Zitat Kutup A, Nentwich MF, Bollschweiler E, Bogoevski D, Izbicki JR, Hölscher AH. What should be the gold standard for the surgical component in the treatment of locally advanced esophageal cancer: transthoracic versus transhiatal esophagectomy. Ann Surg. 2014;260(6):1016–22.PubMedCrossRef Kutup A, Nentwich MF, Bollschweiler E, Bogoevski D, Izbicki JR, Hölscher AH. What should be the gold standard for the surgical component in the treatment of locally advanced esophageal cancer: transthoracic versus transhiatal esophagectomy. Ann Surg. 2014;260(6):1016–22.PubMedCrossRef
7.
Zurück zum Zitat Davies AR, Sandhu H, Pillai A, Sinha P, Mattsson F, Forshaw MJ, et al. Surgical resection strategy and the influence of radicality on outcomes in oesophageal cancer. Br J Surg. 2014;101(5):511–7.PubMedCrossRef Davies AR, Sandhu H, Pillai A, Sinha P, Mattsson F, Forshaw MJ, et al. Surgical resection strategy and the influence of radicality on outcomes in oesophageal cancer. Br J Surg. 2014;101(5):511–7.PubMedCrossRef
8.
Zurück zum Zitat Duan X-F, Tang P, Shang X-B, Jiang H-J, Yu Z-T. The prevalence of lymph node metastasis for pathological T1 esophageal cancer: a retrospective study of 143 cases. Surg Oncol. 2018;27(1):1–6.PubMedCrossRef Duan X-F, Tang P, Shang X-B, Jiang H-J, Yu Z-T. The prevalence of lymph node metastasis for pathological T1 esophageal cancer: a retrospective study of 143 cases. Surg Oncol. 2018;27(1):1–6.PubMedCrossRef
9.
Zurück zum Zitat Newton AD, Predina JD, Xia L, Roses RE, Karakousis GC, Dempsey DT, et al. Surgical management of early-stage esophageal adenocarcinoma based on lymph node metastasis risk. Ann Surg Oncol. 2018;25(1):318–25.PubMedCrossRef Newton AD, Predina JD, Xia L, Roses RE, Karakousis GC, Dempsey DT, et al. Surgical management of early-stage esophageal adenocarcinoma based on lymph node metastasis risk. Ann Surg Oncol. 2018;25(1):318–25.PubMedCrossRef
10.
Zurück zum Zitat Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011;60(11):1449–72.PubMedCrossRef Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011;60(11):1449–72.PubMedCrossRef
11.
Zurück zum Zitat Darling G. The role of lymphadenectomy in esophageal cancer. J Surg Oncol. 2009;99(4):189–93.PubMedCrossRef Darling G. The role of lymphadenectomy in esophageal cancer. J Surg Oncol. 2009;99(4):189–93.PubMedCrossRef
12.
Zurück zum Zitat Hosch S, Kraus J, Scheunemann P, Izbicki JR, Schneider C, Schumacher U, et al. Malignant potential and cytogenetic characteristics of occult disseminated tumor cells in esophageal cancer. Cancer Res. 2000;60(24):6836–40.PubMed Hosch S, Kraus J, Scheunemann P, Izbicki JR, Schneider C, Schumacher U, et al. Malignant potential and cytogenetic characteristics of occult disseminated tumor cells in esophageal cancer. Cancer Res. 2000;60(24):6836–40.PubMed
13.
Zurück zum Zitat Izbicki JR, Hosch SB, Pichlmeier U, Rehders A, Busch C, Niendorf A, et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med. 1997;337(17):1188–94.PubMedCrossRef Izbicki JR, Hosch SB, Pichlmeier U, Rehders A, Busch C, Niendorf A, et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med. 1997;337(17):1188–94.PubMedCrossRef
14.
Zurück zum Zitat Glickman JN, Torres C, Wang HH, Turner JR, Shahsafaei A, Richards WG, et al. The prognostic significance of lymph node micrometastasis in patients with esophageal carcinoma. Cancer. 1999;85(4):769–78.PubMedCrossRef Glickman JN, Torres C, Wang HH, Turner JR, Shahsafaei A, Richards WG, et al. The prognostic significance of lymph node micrometastasis in patients with esophageal carcinoma. Cancer. 1999;85(4):769–78.PubMedCrossRef
15.
Zurück zum Zitat Vazquez-Sequeiros E, Wang L, Burgart L, Harmsen W, Zinsmeister A, Allen M, et al. Occult lymph node metastases as a predictor of tumor relapse in patients with node-negative esophageal carcinoma. Gastroenterology. 2002;122(7):1815–21.PubMedCrossRef Vazquez-Sequeiros E, Wang L, Burgart L, Harmsen W, Zinsmeister A, Allen M, et al. Occult lymph node metastases as a predictor of tumor relapse in patients with node-negative esophageal carcinoma. Gastroenterology. 2002;122(7):1815–21.PubMedCrossRef
16.
Zurück zum Zitat Talsma AK, Xinxue CJO, Pieter L, Wijnhoven BPL, Ong C-AJ, Liu X, et al. Location of lymph node involvement in patients with esophageal adenocarcinoma predicts survival. World J Surg. 2014;38(1):106–13.CrossRef Talsma AK, Xinxue CJO, Pieter L, Wijnhoven BPL, Ong C-AJ, Liu X, et al. Location of lymph node involvement in patients with esophageal adenocarcinoma predicts survival. World J Surg. 2014;38(1):106–13.CrossRef
17.
Zurück zum Zitat Phillips AW, Lagarde SM, Navidi M, Disep B, Griffin SM. Impact of extent of lymphadenectomy on survival, post neoadjuvant chemotherapy and transthoracic esophagectomy. Ann Surg. 2017;265(4):750–6.PubMedCrossRef Phillips AW, Lagarde SM, Navidi M, Disep B, Griffin SM. Impact of extent of lymphadenectomy on survival, post neoadjuvant chemotherapy and transthoracic esophagectomy. Ann Surg. 2017;265(4):750–6.PubMedCrossRef
18.
Zurück zum Zitat McK Manson J, Beasley WD. A personal perspective on controversies in the surgical management of oesophageal cancer. Ann R Coll Surg Engl. 2014;96(8):575–8.PubMedPubMedCentralCrossRef McK Manson J, Beasley WD. A personal perspective on controversies in the surgical management of oesophageal cancer. Ann R Coll Surg Engl. 2014;96(8):575–8.PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Sobin LH. TNM classification of malignant tumours. 7th ed. New York: Wiley; 2009. Sobin LH. TNM classification of malignant tumours. 7th ed. New York: Wiley; 2009.
20.
Zurück zum Zitat Phillips AW, Dent B, Navidi M, Immanuel A, Griffin SM. Trainee involvement in Ivor Lewis esophagectomy does not negatively impact outcomes. Ann Surg. 2018;267(1):94–8.PubMedCrossRef Phillips AW, Dent B, Navidi M, Immanuel A, Griffin SM. Trainee involvement in Ivor Lewis esophagectomy does not negatively impact outcomes. Ann Surg. 2018;267(1):94–8.PubMedCrossRef
21.
Zurück zum Zitat Lagarde SM, Phillips AW, Navidi M, Disep B, Griffin SM. Clinical outcomes and benefits for staging of surgical lymph node mapping after esophagectomy. Dis Esophagus. 2017;30(12):1–7.PubMedCrossRef Lagarde SM, Phillips AW, Navidi M, Disep B, Griffin SM. Clinical outcomes and benefits for staging of surgical lymph node mapping after esophagectomy. Dis Esophagus. 2017;30(12):1–7.PubMedCrossRef
22.
Zurück zum Zitat Mapstone N. Dataset for the histopahtological reporting of oesophageal carcinoma. 2nd ed. 2007. Mapstone N. Dataset for the histopahtological reporting of oesophageal carcinoma. 2nd ed. 2007.
23.
Zurück zum Zitat Schaaf MVD, Johar A, Wijnhoven B, Lagergren P, Lagergren J, van der Schaaf M, et al. Extent of lymph node removal during esophageal cancer surgery and survival. JNCI J Natl Cancer Inst. 2015; 107(5):djv043–djv043. Schaaf MVD, Johar A, Wijnhoven B, Lagergren P, Lagergren J, van der Schaaf M, et al. Extent of lymph node removal during esophageal cancer surgery and survival. JNCI J Natl Cancer Inst. 2015; 107(5):djv043–djv043.
24.
Zurück zum Zitat Lagergren J, Mattsson F, Zylstra J, Chang F, Gossage J, Mason R, et al. Extent of lymphadenectomy and prognosis after esophageal cancer surgery. JAMA Surg. 2015;1–8. Lagergren J, Mattsson F, Zylstra J, Chang F, Gossage J, Mason R, et al. Extent of lymphadenectomy and prognosis after esophageal cancer surgery. JAMA Surg. 2015;1–8.
25.
Zurück zum Zitat Veloski J, Boex JR, Grasberger MJ, Evans A, Wolfson DB. Systematic review of the literature on assessment, feedback and physicians’ clinical performance: BEME Guide No. 7. Med Teach. 2006;28(2):117–28.PubMedCrossRef Veloski J, Boex JR, Grasberger MJ, Evans A, Wolfson DB. Systematic review of the literature on assessment, feedback and physicians’ clinical performance: BEME Guide No. 7. Med Teach. 2006;28(2):117–28.PubMedCrossRef
26.
Zurück zum Zitat Omloo JMT, Lagarde SM, Hulscher JBF, Reitsma JB, Fockens P, van Dekken H, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus. Ann Surg. 2007;246(6):992–1001.PubMedCrossRef Omloo JMT, Lagarde SM, Hulscher JBF, Reitsma JB, Fockens P, van Dekken H, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus. Ann Surg. 2007;246(6):992–1001.PubMedCrossRef
27.
28.
Zurück zum Zitat Hagens ERC, van Berge Henegouwen MI, van Sandick JW, Cuesta MA, van der Peet DL, Heisterkamp J, et al. Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study. BMC Cancer. 2019;19(1):662.PubMedPubMedCentralCrossRef Hagens ERC, van Berge Henegouwen MI, van Sandick JW, Cuesta MA, van der Peet DL, Heisterkamp J, et al. Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study. BMC Cancer. 2019;19(1):662.PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Sinclair RCF, Phillips AW, Navidi M, Griffin SM, Snowden CP. Pre-operative variables including fitness associated with complications after oesophagectomy. Anaesthesia. 2017;72(12):1501–7.PubMedCrossRef Sinclair RCF, Phillips AW, Navidi M, Griffin SM, Snowden CP. Pre-operative variables including fitness associated with complications after oesophagectomy. Anaesthesia. 2017;72(12):1501–7.PubMedCrossRef
30.
Zurück zum Zitat Low DE, Kuppusamy MK, Alderson D, Cecconello I, Chang AC, Darling G, et al. Benchmarking complications associated with esophagectomy. Ann Surg. 2019;269(2):291–8.PubMedCrossRef Low DE, Kuppusamy MK, Alderson D, Cecconello I, Chang AC, Darling G, et al. Benchmarking complications associated with esophagectomy. Ann Surg. 2019;269(2):291–8.PubMedCrossRef
31.
Zurück zum Zitat Mariette C, Markar SR, Dabakuyo-Yonli TS, Meunier B, Pezet D, Collet D, et al. Hybrid minimally invasive esophagectomy for esophageal cancer. N Engl J Med. 2019;380(2):152–62.CrossRefPubMed Mariette C, Markar SR, Dabakuyo-Yonli TS, Meunier B, Pezet D, Collet D, et al. Hybrid minimally invasive esophagectomy for esophageal cancer. N Engl J Med. 2019;380(2):152–62.CrossRefPubMed
32.
Zurück zum Zitat Navidi M, Phillips AW. Hybrid minimally invasive esophagectomy for esophageal cancer. N Engl J Med. 2019;380(17):e28.PubMedCrossRef Navidi M, Phillips AW. Hybrid minimally invasive esophagectomy for esophageal cancer. N Engl J Med. 2019;380(17):e28.PubMedCrossRef
33.
Zurück zum Zitat Tapias LF, Mathisen DJ, Wright CD, Wain JC, Gaissert HA, Muniappan A, et al. Outcomes with open and minimally invasive ivor lewis esophagectomy after neoadjuvant therapy. Ann Thorac Surg. 2016;101(3):1097–103.PubMedCrossRef Tapias LF, Mathisen DJ, Wright CD, Wain JC, Gaissert HA, Muniappan A, et al. Outcomes with open and minimally invasive ivor lewis esophagectomy after neoadjuvant therapy. Ann Thorac Surg. 2016;101(3):1097–103.PubMedCrossRef
Metadaten
Titel
Impact of Lymphadenectomy on Survival After Unimodality Transthoracic Esophagectomy for Adenocarcinoma of Esophagus
verfasst von
A. W. Phillips, MD, MA, FRCSEd (Gen.Surg)
K. Hardy, BSc
M. Navidi, MB, ChB, FRCSEd (Gen.Surg)
S. K. Kamarajah, BMedSci, MBChB
A. Madhavan, MB, ChB, MRCS
A. Immanuel, MD, FRCSEd
S. M. Griffin, OBE, MD, PRCSEd
Publikationsdatum
11.10.2019
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 3/2020
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07905-8

Weitere Artikel der Ausgabe 3/2020

Annals of Surgical Oncology 3/2020 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.